CryoCath’s Arctic Front for atrial fibrillation
This article was originally published in The Gray Sheet
Executive Summary
Pivotal stage of the STOP AF trial assessing CryoCath's Arctic Front cryo-balloon catheter for treating atrial fibrillation gains conditional FDA investigational device exemption. Patient enrollment will begin within "weeks," the firm says Sept. 5. The randomized, five-center study will include 75 highly symptomatic paroxysmal AF patients who have failed at least one anti-arrhythmic drug, and will compare Arctic Front treatment with standard drug therapy. The trial's primary endpoint will be absence of AF at 12-month follow-up. Originally expected to begin in Q2, the trial has been delayed by device design changes (1"The Gray Sheet" April 10, 2006, In Brief)...
You may also be interested in...
CryoCath pivotal trial delayed
FDA is requiring CryoCath to enroll 15 additional patients in its feasibility study for the Arctic Front cryoablation system to treat atrial fibrillation in order to assess design changes made to the catheter, firm announces April 3. The 15 additional patients have been identified and will be enrolled at two additional U.S. sites, accord-ing to CryoCath. Still, the pivotal stage of the STOP-AF trial, originally anticipated to begin in the second quarter, will likely be pushed back. Principle investigator Douglas Packer, MD, Mayo Clinic, announced in January that 13 of the initial 15 patients in the feasibility study were free of atrial fibrillation at three months (1"The Gray Sheet" Jan. 23, 2005, p. 9)...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.